Browse Articles

Discover research articles across all indexed journals

Low‐Temperature Resistant and Biocompatible Hot‐Melt Adhesives Enabled by Triblock Thermoplastic Polyester Elastomers

Advanced Materials He He, Xiaoyu Zhang, Mingqian Wang et al. Jul 01, 2026 DOI: 10.1002/adma.202521551

ABSTRACT The state‐of‐art commercial polymeric adhesives are mainly petroleum‐based, non‐biodegradable and not tolerant of low temperature, severely limiting their applications in extremely cold regions. Current research efforts focus on development of sustainable and biodegradable polyester‐based adhesives. However, nearly all the reported polyester‐based adhesives were used at room temperature, and the innovative functional polyester‐based adhesives with low‐temperature‐resistance are very rare. Herein, we rationally designed and synthesized triblock thermoplastic polyester elastomers, poly(1,4‐dioxan‐2‐one)‐ b ‐poly( γ ‐methyl‐ ε ‐caprolactone)‐ b ‐poly(1,4‐dioxan‐2‐one) (PPDO‐ b ‐PMCL‐ b ‐PPDO), serving as high‐performance biodegradable hot‐melt adhesive with excellent low‐temperature‐resistance. The mechanical and viscoelastic properties of polyester‐based adhesives could be readily modulated by varying molecular weight and fraction of hard/soft blocks via controlled ring‐opening polymerization. PPDO‐ b ‐PMCL‐ b ‐PPDO with appropriate volume fraction of hard blocks exhibited strong adhesion to a range of substrates (with a bonding strength high up to 5.0 MPa) both at room temperature and even at cryogenic temperature (−196°C). The polyester elastomer‐based adhesives outperformed some common commercial petroleum‐based hot‐melt adhesives, showing their great potential in the specific scenarios like polar‐region exploration.

Data‐Driven Insights into the High‐Throughput Design of Weakly Solvating Electrolytes for Lithium Metal Batteries

Advanced Materials Yu‐Chen Gao, Zhen‐Ning Guo, Yi‐Lin Niu et al. Jul 01, 2026 DOI: 10.1002/adma.73537

ABSTRACT Weakly solvating electrolytes (WSEs) have emerged as an effective strategy for stabilizing lithium (Li) metal anodes. However, their molecular design remains largely empirical, and a unified set of design criteria applicable across chemical families is still lacking. Herein, we establish a quantitative design framework that encodes structural motifs and key physicochemical properties of 236 875 organic molecules into six transferable descriptors governing Li + solvation. Through a hierarchical and chemistry‐informed screening workflow, this vast chemical space is converted into a tractable weak solvation landscape, from which 643 redox‐robust candidates are identified. Clustering and scaffold analysis reveal chemically coherent regions within this landscape and further uncover transferable molecular design handles, most notably α ‐branching and distributed fluorination, both of which exhibit volcano‐type relationships that enable predictable tuning of solvation strength. An interactive visualization platform is further developed to render this landscape readily navigable, thereby enabling similarity‐guided discovery and structure‐resolved interrogation. By transforming weak solvation from an empirical qualitative label into a quantitatively programmable design coordinate, this work provides an open and generalizable foundation for electrolyte development in Li metal batteries and, more broadly, for data‐driven discovery of advanced electrolyte molecules.

Real-world incidence and spectrum of immune-related toxicity in cancer patients: A registry cohort data from a Central Coast Cancer Centre.

Journal of Clinical Oncology Dmitrii Shek, Matthew Chan, Fiona Dixon et al. Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.318

318 Background: Immune-checkpoint inhibitors (ICIs) have transformed outcomes across a broad range of solid malignancies, however immune-related adverse events (irAEs) remain a major source of morbidity, treatment interruption and healthcare utilisation. Data from real-world, particularly in regional areas, remains limited. We aimed to characterise the incidence, grading and treatment context of irAEs among patients treated with ICIs across multiple tumour types within a large regional Australian health district. Methods: We conducted a retrospective cohort study of adult patients treated with ICIs between 2017 and 2026 at Gosford and Wyong tertiary hospitals of Australian Central Coast. Eligible patients had a confirmed diagnosis of solid malignancy and received at least one dose of an ICI. Clinical data collected included demographics, cancer type, line of therapy, therapeutic regimen and documented irAEs graded according to CTCAE criteria (version 6.0). Results: A total of N = 974 patients were included. Treatment exposure consisted of single-agent checkpoint inhibitor in 42% (n = 412), chemoimmunotherapy in 43% (n = 419), and combination ICI in 15% (n = 143). Overall, 156 patients (16%) developed at least one irAE. The most common irAEs were dermatologic (38/156), gastrointestinal (29/156), hepatic (25/156), endocrine (21/156) musculoskeletal (18/156) and pulmonary (17/156) toxicities. Rare but clinically significant irAEs included ocular toxicity (2/156), bullous pemphigoid (2/156), neuropathy (3/156), adrenal insufficiency (6/156) and acute kidney injury (8/156). Grade ≥3 irAEs occurred in 20% (31/156) of patients. 8% (12/156) of patients experienced multisystem immune toxicity involving more than one organ system. Treatment interruption due to irAEs occurred in 68% (106/156) and permanent discontinuation in 34% (54/156). Hospitalisation related to irAEs was required in 22% (35/156) of cases, with systemic corticosteroids representing the mainstay of management and selected cases (13/156) requiring escalation to advanced immunosuppressive therapy (infliximab, IVIG, mycophenolate mofetil). Conclusions: Our findings underscore the importance of early recognition, multidisciplinary management and risk stratification in routine practice. This study provides valuable real-world evidence of irAEs from a regional cancer centre highlighting the heterogeneity and clinical burden of toxicity and supports ongoing efforts to optimise toxicity surveillance and management as ICI use continues to expand.

Daratumumab in the frontline management of newly diagnosed multiple myeloma: An overview of systematic reviews and meta-analyses.

Journal of Clinical Oncology Riddhi Solanki, Manju Sengar, Hasmukh Jain Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.248

248 Background: We conducted an overview of systematic reviews and meta-analyses (SRMAs) to evaluate daratumumab’s effect on overall survival (OS) in frontline newly diagnosed multiple myeloma (NDMM), as OS benefit remains uncertain despite improved progression-free survival. Methods: Registered in PROSPERO (CRD420261298985), we searched 4 databases from inception to January 31, 2026 for SRMAs evaluating daratumumab-based induction regimens reporting OS estimates. Method quality assessed using AMSTAR-2 and certainty of evidence using GRADE. Results: 8 SRMAs (2019–2025) were included, synthesizing a mean of 8.2 daratumumab-specific RCTs per review. Across regimens, daratumumab-containing therapy consistently reduced mortality vs. standard regimens, with varied certainty. The most robust OS benefit was observed with D-VTd (CASSIOPEIA: HR 0.55, 95% CI 0.42–0.73; high certainty) and D-Rd (MAIA: HR 0.67, 95% CI 0.55–0.82; high certainty). D-VMp also showed survival improvement (ALCYONE: HR 0.56, 95% CI 0.46–0.68; moderate certainty). For D-VRd, OS favored daratumumab but was imprecise (GRIFFIN: HR 0.90, 95% CI 0.31–2.56; moderate certainty). Evidence for D-VCd was limited (HR 1.33, 95% CI 0.69–2.55; low), and no mature OS data for D-KRd (very low certainty). Overall OS evidence was rated moderate, primarily downgraded for imprecision. Conclusions: Adding daratumumab improves OS in NDMM, supported by moderate-to-high certainty evidence with the most mature benefit seen for D-VTd, D-Rd, and D-VRd, supporting routine use; however, comparator arms are often inferior (quadruplets vs triplets vs doublets), limiting incremental inference. Longer follow-up is needed to clarify optimal sequencing. OS outcomes associated with frontline daratumumab-based regimens in newly diagnosed multiple myeloma (NDMM). Hazard ratios (HRs) <1.0 favor daratumumab-containing therapy over standard-of-care comparator regimens. Treatment Regimen Trial Name/Patients OS Hazards Ratio [95% CI] Quality of Evidence D-VTd vs. VTd CASSIOPEIA/543 0.55 (0.42–0.73) High D-VRd vs. VRd GRIFFIN/104CEPHEUS/197PERSEUS/358 0.90 (0.31–2.56)0.85 (0.58–1.24)0.73 (0.47–1.14) Moderate a, b D-Rd vs. Rd MAIA/368 0.67 (0.55–0.82) High D-VMd vs. VMd ALCYONE2017/350OCTANS/146 0.56 (0.46-0.68)0.60 (0.35-1.03) Moderate b D-VCd vs. VCd AMaRC 03-16 (64) 1.33 (0.692- 2.549) Low a, c D-KRd vs. KRd GEM2017FIT NR Very Low d D, daratumumab; V, bortezomib; T, thalidomide; R, lenalidomide; M, melphalan; C, cyclophosphamide; K, carfilzomib; d, dexamethasone; HR, hazard ratio; CI, confidence interval; NR, not reported. a Imprecision; 95% CI around the HR is wide and crosses unity. b Imprecision; contributing trial reporting reported interim OS data. c Imprecision; limited number of OS events across contributing trials. d Absence of reported overall OS from the trial.

HPLC-QTOF-MS/MS-based metabolomic profiling combined with chemometric analysis links lichen metabolites to anti-inflammatory activity

Scientific Reports Izabela Baczewska, Christian Zidorn, Thomas Stegemann et al. Jul 01, 2026 DOI: 10.1038/s41598-026-58500-3

Abstract Lichens are a rich source of bioactive secondary metabolites with potential anti-inflammatory properties. This study involved the comprehensive phytochemical profiling of 39 lichen species collected in eastern Poland using HPLC-QTOF-MS/MS, combined with chemometric analysis and biological activity testing. After data processing, a total of 91 compounds were identified, with depsides and depsidones constituting the dominant chemical classes. Multivariate analyses (PCA and PLS-DA) revealed distinct metabolomic patterns among the species and highlighted the relationship between metabolite composition and biological activity. The anti-inflammatory potential of lichen extracts was evaluated in LPS-stimulated macrophages by measuring the levels of intracellular reactive oxygen species (ROS), nitric oxide (NO) and cyclooxygenase-2 (COX-2) activity. Most extracts significantly reduced ROS levels, indicating a consistent antioxidant effect. In contrast, modulation of NO and COX-2 was more variable and generally less pronounced. Chemometric analyses suggested that multiple metabolites contribute to the observed anti-inflammatory activity, with evidence of an inverse relationship between ROS reduction and COX-2 inhibition. Although some compounds were found to be associated with biological effects, the results indicate that these effects are likely to be driven by the complex interactions within the extracts rather than by the action of individual constituents. Overall, lichens emerge as promising sources of anti-inflammatory agents, primarily acting through antioxidant mechanisms.

Competing programs shape cortical sensorimotor–association axis development

Nature Jeremiah Tsyporin, Menglei Zhang, Cai Qi et al. Jul 01, 2026 DOI: 10.1038/s41586-026-10699-x

Engineering CO <sub>2</sub> Reduction Pathways via Alloy‐Support Interactions in Li‐CO <sub>2</sub> Batteries

Advanced Materials Liang Sun, Xindan Zhang, Guang Feng et al. Jul 01, 2026 DOI: 10.1002/adma.73809

ABSTRACT Rechargeable Li‐CO 2 batteries (LCBs) hold great promise for dual‐function CO 2 utilization and energy storage, yet their practical application is hindered by the sluggish kinetics of the conventional Li 2 CO 3 pathway, resulting in low discharge voltages (below 2.0 V) and large overpotentials (over 1.0 V). Herein, we propose a strategy of CO 2 reduction pathway engineering via alloy‐support interaction to unlock high‐performance LCBs. We designed a Ru 2 Cu 4 /NC 1000 catalyst, where spectroscopy confirms distinct charge redistribution driven by strong coordination between the Ru 2 Cu 4 alloy and N‐doped support. Theoretical simulations validate that this interaction shifts the Ru and Cu d‐band centers toward the Fermi level and induces interfacial charge redistribution, thus optimizing the electronic structure of the Ru‐Cu active sites for CO 2 reduction. More importantly, this electronic restructuring thermodynamically favors the formation of metastable Li 2 C 2 O 4 over insulating Li 2 CO 3 , thus significantly reducing the activation energy barrier for the rate‐determining step by 0.56 eV. As a result, the cell achieves a minimal overpotential of 0.50 V, an exceptional discharge voltage of 3.23 V, and a high specific capacity of 33 922 mAh g −1 (at 100 mA g −1 ). Our work establishes electron‐state engineering via alloy‐support interactions as a protocol for directing reaction pathways and achieving high‐voltage and durable LCBs.

Indium‐Mediated Glue‐Like Interlayer Enables Stable High‐Capacity Flexible Sodium Metal Batteries

Advanced Materials Xinyan Li, Shujing Wen, Junhua Zhou et al. Jul 01, 2026 DOI: 10.1002/adma.73556

ABSTRACT Na metal is considered as a highly promising anode material for Na batteries, owing to its high theoretical capacity (1166 mAh g −1 ) and low redox potential (−2.71 V vs. SHE). However, its practical application is significantly hindered by interfacial instability and dendrite formation arising from uneven Na deposition, which severely compromise its cycling lifespan. Herein, we develop a robust three‐dimensional glue‐like interlayer via in situ electrochemical conversion of CuInS 2 on a flexible Cu current collector. This process yields a Na 2 S/Na 5 InS 4 /Cu composite interlayer of strong interphase connections, ensuring tight interfacial connections and exceptional mechanical stability throughout extended cycling, thereby effectively mitigating interfacial degradation. With this interlayer, the Na metal anode achieves a high Coulombic efficiency over 99.4%, outstanding symmetrical cell stability exceeding 2400 hours, and excellent high‐capacity full cell cycling (95.3% capacity retention after 1000 cycles). Flexible pouch cells retain 95% capacity over 200 cycles and endure more than 10,000 bending.

Pivotal PYNNACLE phase 2 trial of rezatapopt in heavily pre-treated, advanced solid tumors with a <i>TP53</i> Y220C mutation: Initial ovarian cancer analysis.

Journal of Clinical Oncology Tira J. Tan, Ecaterina Elena Dumbrava, Jean-Sebastien Frenel et al. Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.201

201 Background: TP53 Y220C mutations occur in ~3% of ovarian cancers. Rezatapopt, an investigational, first-in-class, p53 reactivator, selectively binds to Y220C-mutated p53, stabilizing it in wildtype conformation and restoring p53 function. Methods: PYNNACLE (NCT04585750) is a pivotal, single-arm phase 2 trial of rezatapopt (2000 mg once daily) in locally advanced or metastatic solid tumors with a TP53 Y220C mutation. Primary endpoint: Overall response rate (ORR; blinded independent central review; RECIST v1.1) across tumor cohorts and in the ovarian cancer cohort. Key secondary endpoints: Investigator-assessed ORR, other efficacy endpoints, safety. Efficacy evaluable: Patients (pts) with first post-baseline tumor assessment or discontinued early. Initial analysis in ovarian cancer is shown. Results: By 4 Sep 2025, of 112 pts receiving rezatapopt, 51 had ovarian cancer. Median age was 67 years (range 46–91), ECOG score was 0 (48%) or 1 (52%), and 49 (96%) pts had high-grade serous ovarian cancer. At study entry, 30 (59%) pts were platinum resistant, 18 (35%) were platinum refractory (primary platinum refractory n=7), and 3 (6%) were platinum sensitive. Pts were heavily pre-treated (median prior lines 4; range 1–10); 40 (78%) had prior bevacizumab. Investigator-assessed ORR (Table) was 46% in efficacy-evaluable pts, 48% in platinum-resistant pts, 44% in platinum-refractory pts, and 46% in pts who had prior bevacizumab. Median time to response and duration of response were 1.3 (range 1.2–1.4) and 8.0 months (range 3.4–not reached), respectively. Treatment-related adverse events (TRAEs) in all pts (N=112) were mostly Grade 1/2; most frequent (&gt;15%): nausea (34%), fatigue (23%), blood creatinine increase (20%), alanine aminotransferase increase (18%). Four pts (ovarian cancer n=1) discontinued due to TRAEs. Conclusions: In this initial analysis of the pivotal PYNNACLE Phase 2 trial, rezatapopt showed clinically meaningful efficacy and manageable safety in heavily pre-treated pts with TP53 Y220C-positive advanced ovarian cancer. Rezatapopt offers promising targeted therapy for ovarian cancer with a TP53 Y220C mutation. Clinical trial information: NCT04585750 . Efficacy evaluable patients All ovarian cancern=48 Platinum resistantn=27 Platinum refractory a n=18 Prior bevacizumabn=37 Prior PARP inhibitor n=29 Folate receptor alpha (FRα) positive b n=21 FRα negative b n=20 Overall response rate, c %(95% CI) 46(31–61) 48(29–68) 44(22–69) 46(30–63) 52(33–71) 48(26–70) 40(19–64) Best response, n Complete response 1 0 0 1 1 0 0 Partial response 18 12 6 14 13 9 6 Unconfirmed partial response d 3 1 2 2 1 1 2 Stable disease 14 8 5 10 7 9 4 Progressive disease 4 2 2 4 2 1 2 Not evaluable 8 4 3 6 5 1 6 a Relapse during or within 1 month of platinum therapy; b FRα expression ≥75% (positive) or &lt;75% (negative) of viable tumor cells; c Complete + partial response (confirmed + unconfirmed); d Pending confirmation.

Multimodal spatiotemporal atlas to reveal CCDC3 <sup>+</sup> CAFs as drivers of liver metastasis in colorectal cancer.

Journal of Clinical Oncology Weiping Zhu Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.25

25 Background: Colorectal cancer liver metastasis (CRLM) exhibits pronounced heterogeneity and dynamic evolution of the immune microenvironment. However, most studies remain limited to static snapshots, hindering identification of key regulatory axes and actionable nodes across multimodal and temporal scales. Methods: We integrated single-cell sequencing with multi-omic analyses to derive a chromosomal instability (CIN) index. To map spatiotemporal progression, we built a multimodal atlas of CRLM by integrating 10× Visium spatial transcriptomics, MALDI-MSI spatial metabolomics, and Olink spatial proteomics, alongside multi-timepoint sampling in humanized PDX models. Positional encoding and adversarial domain adaptation corrected modality- and batch-specific effects, achieving subcellular-scale alignment and a high-fidelity spatiotemporal feature matrix. Graph neural network–based analyses quantified spatial gradients and interactions among CCDC3⁺ CAFs, Tregs, and CD8⁺ T cells. To decode high-dimensional spatiotemporal signals, we developed a physics-informed deep dynamic model (SpaTemNet-PINN) that integrates spatial topology with temporal dependencies and embeds diffusion–reaction kinetic constraints; key model-predicted nodes were validated by CRISPRi. Finally, reinforcement learning modeled optimal dosing schedules for combined CCDC3/CDT1 blockade with PD-1 inhibition, and a spatial immune scoring system was established for patient stratification and longitudinal monitoring. Results: We identified CAF-derived CCDC3 as a central driver linking stromal remodeling to CIN, demonstrating that CCDC3 engages CXCR3 on tumor cells to activate STAT3 phosphorylation and induce CDT1 transcription, establishing a CCDC3/CXCR3/STAT3/CDT1 axis that promotes proliferation, metastasis, and CIN. The spatiotemporal atlas resolved an immune-excluded niche marked by coordinated spatial gradients of CCDC3⁺ CAFs and Tregs alongside CD8⁺ T-cell depletion. SpaTemNet-PINN quantitatively captured how CCDC3 gradients perturb PCNA–CDT1 homeostasis and shape CIN trajectories, with CRISPRi validating key regulators. CIN-associated DAMPs–NETs shielding structures were spatially linked to impaired CD8⁺ T-cell infiltration. Reinforcement learning–guided simulations optimized dual CCDC3/CDT1 blockade with PD-1 inhibition and informed a spatial immune score for patient stratification and dynamic response monitoring. Conclusions: This study establishes an integrated framework—from mechanistic dissection to spatially informed therapeutic intervention—providing systematic evidence for understanding the spatiotemporal nature of immune exclusion in CRLM and advancing precision therapeutic strategies.

Contra-Thermodynamic α,β- to β,γ-Photodeconjugation of an Inert CO <sub>2</sub> -Derived δ-Lactone Enables Facile Ring-Opening Polymerization

Journal of the American Chemical Society Arron C. Deacy, Christopher K. Webber, Ian A. Tonks Jul 01, 2026 DOI: 10.1021/jacs.6c07186

First-line ibrutinib plus venetoclax for non-blastoid mantle cell lymphoma in patients ≥65 years or with TP53 mutations

Blood Michael Wang, Marc S Hoffmann, Tomasz Wróbel et al. Jul 01, 2026 DOI: 10.1182/blood.2025032833

The phase 3 SYMPATICO study included an open-label cohort to evaluate the efficacy and safety of first-line ibrutinib plus venetoclax in patients with non-blastoid mantle cell lymphoma (MCL) ≥65 years (n=65), or ≥18 years with a TP53 mutation (TP53m) (n=11). Eligible patients received oral ibrutinib 560 mg once daily and venetoclax (5-week ramp-up to 400 mg once daily) for 2 years, then single-agent ibrutinib 560 mg until disease progression or unacceptable toxicity. In total, 78 patients were enrolled. With median time on study of 40.5 months (range, 0.6+ to 46.9), the complete response (CR) rate was 69% (95% CI, 58-79), and the overall response rate was 95% (95% CI, 87-99). The median duration of response was 37.1 months (95% CI, 30.3-not estimable [NE]). Median progression-free survival (mPFS) was 40.2 months (95% CI, 29.4-NE); median overall survival (OS) was not reached (3-year OS rate, 79% [95% CI, 68-86]). In patients ≥65 years, CR rates were 76% (no TP53m) and 44% (with TP53m), mPFS was 40.2 and 22.0 months, and 3-year OS was 85% and 66%, respectively. In adult patients &amp;lt;65 years (with TP53m), the CR rate was 73%, mPFS was 15.4 months, and 3-year OS was 73%. The most common treatment-emergent adverse events were diarrhea (49%), fatigue (37%), neutropenia (35%), and COVID-19 (32%). First-line ibrutinib plus venetoclax showed promising efficacy, with high CR rates and durable remissions, in patients with previously untreated non-blastoid MCL and may be an option for patients ≥65 years or patients of any age with TP53m. NCT03112174

Mechanisms of Xiangxue decoction in treating COVID-19 via HPLC‒Q-TOF‒MS/MS, network pharmacology, molecular docking and molecular dynamics simulation

Scientific Reports Yuan Ma, Donghui Lu, Yuhong Ge et al. Jul 01, 2026 DOI: 10.1038/s41598-026-45496-z

Ibrutinib improves overall survival in patients with mantle cell lymphoma

Nature Reviews Clinical Oncology Peter Sidaway Jul 01, 2026 DOI: 10.1038/s41571-026-01166-7

Enhanced Photocatalytic H <sub>2</sub> O <sub>2</sub> Production on Terpyridine‐Based Acrylonitrile‐Linked Covalent Organic Frameworks with Asymmetric Localized Electron Distribution

Advanced Materials Qinglan Zhao, Mengmeng Ce, Hengtao Lei et al. Jul 01, 2026 DOI: 10.1002/adma.73821

ABSTRACT Covalent organic frameworks (COFs) serve as promising photocatalysts for sustainable photosynthesis of H 2 O 2 from water and air due to their well‐defined architecture and precisely controllable structure. The key to achieving high H 2 O 2 production rates lies in the efficient adsorption of O 2 and effective charge transfer over COFs. In this work, we have studied a terpyridine‐based acrylonitrile‐linked COF (TPy‐acr COF) with optimum localized electron distribution and enhanced charge transfer for two‐electron transfer oxygen reduction toward H 2 O 2 production. The electron‐deficient pyridine nitrogen atoms in the terpyridine unit induce an asymmetric electron distribution with localized electron density at the adjacent carbon atoms, while the electron‐withdrawing acrylonitrile linkage increases the electron distribution asymmetry of the entire framework. Consequently, the high electron‐density carbon atoms in the terpyridine units of TPy‐acr COF show strong binding for O 2 and fast charge transfer to the key intermediate * OOH. Remarkably, the TPy‐acr COF enabled a high production rate of 4.85 mmol g −1 h −1 for H 2 O 2 directly from water and air. An outdoor scale‐up experiment shows an average H 2 O 2 production rate of 1.14 mmol g −1 h −1 over TPy‐acr COF using water in ambient air under natural sunlight, demonstrating practical application potential with sustainability, simplicity, and scalability.

Orbital‐Hybridizable Nanoseed Interphase Enables One‐Minute Rechargeable, Energy‐Dense Anode‐Free Aqueous Zinc Batteries

Advanced Materials Won‐Yeong Kim, Ahyeon Son, Ohchan Kwon et al. Jul 01, 2026 DOI: 10.1002/adma.73553

ABSTRACT Aqueous zinc (Zn) batteries are emerging as promising candidates for energy storage systems (ESS) and wearable electronics, but their practical application is hindered by low energy density and electrochemical instability at the Zn anode–electrolyte interface. Here, we report an orbital‐hybridizable nanoseed (OHNS) interphase composed of graphene oxide nanoribbons (GONRs) uniformly deposited on Cu current collectors via a scalable slot‐die coating process, enabling one‐minute‐rechargeable, energy‐dense anode‐free aqueous Zn batteries. The carbon edges (C‐edges) prevalent in the GONR facilitate orbital hybridization with Zn. This chemical interplay between the heteroatoms (C‐edge and Zn) enhances Zn nucleation kinetics and retards surface diffusion of adsorbed Zn, thereby promoting corrosion‐resistant, (002)‐oriented growth of Zn. Consequently, reversible Zn plating/stripping with high Coulombic efficiency (∼99.5%) was achieved even at a high current density of 120 mA cm −2 . Moreover, anode‐free full cells with the OHNS interphase delivered a maximum energy/power density of 140.6 Wh kg −1 /4138.1 W kg −1 . Notably, anode‐free pouch cells exhibited stable capacity retention of 82.2% after 800 cycles at a fast charge/discharge current density of 106C (equivalent to a time of 34 s).

Hexosamine biosynthesis drives hemocyanin O-GlcNAcylation to potentiate antibacterial immunity in shrimp

Journal of Biological Chemistry Qian Feng, Maoshuai Fu, Wei Wang et al. Jul 01, 2026 DOI: 10.1016/j.jbc.2026.113213

National cancer control plans in Southeast Asia: A systematic comparison.

Journal of Clinical Oncology Adrian E. Go, Harenthri Devy Alagir Rajah, Soehartati Gondhowiardjo et al. Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.327

327 Background: Southeast Asia (SEA) is experiencing a significant increase in cancer burden with 1.15 million new cases recorded in 2022; and 1.4 million deaths projected to occur by 2050.Central to the region’s response to this burden are the National Cancer Control Plans (NCCPs), which remain poorly characterized. Therefore we performed a systematic analysis to compare NCCPs across the 11 SEA nations with each other and against UN and WHO cancer control frameworks in an effort to better inform national policy building. Methods: Data was taken from the International Cancer Control Partnership (ICCP) portal 11 and official government websites to identify the most recent NCCPs or functionally equivalent policies. The content and alignment of NCCPs were mapped against frameworks informed by the WHO Assessment Tool , and previous frameworks. Plans were mapped by structure (duration, type, governance, health workforce, financing, health information systems, and monitoring and evaluation), by service delivery scope, by stakeholders involved, by health workforce engaged, by vulnerable populations covered, and against WHO and UN global strategies of cancer care and non-communicable diseases. Results: Among the 11 SEA countries, only 6 were stand-alone plans. All were under the ministries of health, most had 5 year implementation cycles, and only 3 had comprehensive financial protection mechanisms. Only 4 had comprehensive referral systems and well-established population based national cancer registries. Preventive strategies largely targeted behavioral risk, HPV, and HBV while early detection focused heavily on cervical (91%) and breast cancer (73%). All prioritized expansion of diagnostic and treatment capacity but few addressed hematopoietic stem cell transplantation and immunotherapy. Few addressed equitable opioid access (45%). All NCCPs had provisions for palliative care but not all addressed bereavement care for caregivers (73%). Medical and surgical oncologists emerged as the most engaged, with medical physicists and patient navigators as the least engaged health workforce. Stakeholder engagement was uneven with community leaders and religious groups being the least engaged. Indigenous Peoples, LGBTQIA+, and Refugees were the least covered vulnerable groups. Alignment with WHO and UN frameworks was uneven (27-91% fully aligned). Conclusions: Our comparative analysis reveals that NCCPs in SEA demonstrate persistent gaps between policy and implementation, are largely ministry of health-centric, demonstrate uneven service delivery, inadequate workforce strategies, limited stakeholder inclusion and coverage of vulnerable populations. Strengthening these plans are critical to closing cancer care gaps and improving inequity driven cancer outcomes across the region.

Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion–Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial

Journal of Clinical Oncology James M. Cleary, Christoph Springfeld, Dirk Arnold et al. Jul 01, 2026 DOI: 10.1200/jco-25-03128

PURPOSE Presently, to our knowledge, there are no approved targeted therapies for neuregulin 1 gene fusion–positive ( NRG1 +) cholangiocarcinoma. Zenocutuzumab, a HER2 × HER3 bispecific antibody, is approved for previously treated, advanced/metastatic NRG1 + non–small cell lung cancer and pancreatic adenocarcinoma. Here, we report results for 22 patients with NRG1 + cholangiocarcinoma in the eNRGy trial. METHODS eNRGy is a single-arm, phase II study of zenocutuzumab in advanced NRG1 + solid tumors. Patients were age 18 years and older and previously treated with or unsuitable for standard therapy. Zenocutuzumab 750 mg was administered intravenously once every 2 weeks. The primary end point was investigator-assessed overall response rate (ORR; RECIST v1.1). Secondary end points included duration of response (DOR), clinical benefit rate (CBR), progression-free survival (PFS), and safety. RESULTS As of July 31, 2025, 22 patients (median age 57.5 years) with advanced NRG1 + cholangiocarcinoma were enrolled and had received a median of 1.0 (range, 0-6) prior therapies. In the 18 patients with tumor subtype data available, all had intrahepatic cholangiocarcinoma. Three patients did not meet the protocol-defined criteria for inclusion in the efficacy analysis. Seven of 19 patients achieved a response, resulting in an ORR of 36.8% (95% CI, 16.3 to 61.6). The median DOR was 7.4 months and the median time to response was 1.9 months. The CBR was 57.9% (95% CI, 33.5 to 79.7). Median PFS was 9.2 months (95% CI, 3.9 to 11.1). Most treatment-related adverse events (TRAEs) were grade 1 and 2, and the most common were diarrhea (27.3%), fatigue (18.2%), and nausea (13.6%). One patient had a grade 3 TRAE of anemia. No patients discontinued treatment due to an AE. CONCLUSION Zenocutuzumab demonstrated clinically meaningful and durable antitumor activity with a favorable safety profile in patients with advanced NRG1+ cholangiocarcinoma.

R spondin 2 regulates regeneration of the hematopoietic stem cell niche

Blood Vanessa N Montinelli, Samantha Grohe, Xue Ying Song et al. Jul 01, 2026 DOI: 10.1182/blood.2025032421

Hematopoietic stem cells (HSCs) depend upon paracrine signals from bone marrow endothelial cells (BM ECs) and perivascular stromal cells for their maintenance and regeneration. Chemotherapy and total body irradiation (TBI) utilized in the curative treatment of cancer cause profound damage to the BM vascular niche, which impedes hematopoietic reconstitution. The mechanisms controlling regeneration of the HSC vascular niche are not well understood. We discovered that conditional deletion of R spondin 2 (Rspo2) from BM endothelial cells (ECs) impaired HSC regeneration in mice following total body irradiation (TBI), in association with decreased HSC survival. Mice lacking EC - Rspo2 expression demonstrated delayed regeneration of the BM vascular niche following TBI and Rspo2 - deficient BM ECs displayed defective angiogenesis. Conversely, systemic administration of R spondin 2 caused early restoration of the BM sinusoidal vascular niche in irradiated mice and augmented BM EC angiogenesis. Concordantly, R spondin 2 - treated mice displayed accelerated regeneration of the HSC pool. These studies suggest that BM ECs regulate the regeneration of the BM sinusoidal vascular niche via secretion of R spondin 2.